A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

NCT07067463 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

705

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis (MS) Primary Progressive

Interventions

DRUG: Orelabrutinib
DRUG: Placebo

Sponsor

Zenas BioPharma (USA), LLC